In this study, we demonstrated that certain CD200 peptides enhance the efficacy of autologous tumor cell lysate therapeutic vaccines in pet dogs with high-grade glioma as evidenced by significantly increased survival times. This evidence concerns the gene CD200 and central nervous system cancer.